Outcome of Board meeting for approval of Un-audited financial results for the quarter ended 30th June, 2025
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts less than Nifty Microcap 250 and 4.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mangalam Drugs and Organics reported a sharp deterioration in Q1 FY26 results. Standalone revenue from operations fell about 25% year-on-year to ₹5,734.87 lakhs (from ₹7,653.62 lakhs in Q1 FY25). The company swung from a net profit of ₹268.47 lakhs in Q1 FY25 to a net loss of ₹1,372.80 lakhs, translating to a negative EPS of ₹(8.67) versus ₹1.70 a year ago. Consolidated results were similar, with a net loss of ₹1,379.83 lakhs. Total expenses remained broadly elevated relative to revenue, which drove the operating loss before tax of ₹1,292.80 lakhs. The statutory auditors (V.S. Somani & Co.) issued an unmodified limited review report, with no qualifications or modified opinions. A pending merger scheme of Mangalam Laboratories Pvt Ltd and Shri JB Pharma Pvt Ltd into the company is awaiting NCLT approval, with a creditors and shareholders meeting scheduled for August 12, 2025.
Negative for shareholders in the short term — significant revenue contraction combined with a swing to a sizeable quarterly loss is likely to weigh on the stock. The clean auditor opinion and the upcoming merger scheme are mild positives, but the weak operating performance is the dominant story.